Petros Pharmaceuticals, Inc.
News
Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
Accesswire Company is currently conducting larger scale comprehension test to confirm results in compliance with FDA discussionsNEW YORK, NY / ACCESSWIRE / September 11, 2024 / Petros Pharmaceuticals, Inc...\n more…
Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Accesswire NEW YORK, NY / ACCESSWIRE / September 3, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter ('OTC') drug...\n more…
Maxim Group Sticks to Its Buy Rating for Petros Pharmaceuticals (PTPI)
TipRanks Financial Blog Maxim Group analyst Naz Rahman reiterated a Buy rating on Petros Pharmaceuticals (PTPI - Research Report) yesterday. The company's shares closed ye...\n more…
PTPI Stock Earnings: Petros Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nPTPI stock results show that Petros Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second...\n more…
Petros Pharmaceuticals (NASDAQ:PTPI) Stock Price Down 10.4%
Ticker Report Petros Pharmaceuticals, Inc. (NASDAQ:PTPI - Get Free Report) shares dropped 10.4% during trading on Monday . The stock traded as low as $0.31 and last traded at $0.35. Approximately 462,862 shares...\n more…